Shareholders appeared unconcerned with Shanghai Fosun Pharmaceutical (Group) Co., Ltd.'s (SHSE:600196) lackluster earnings report last week. We think that the softer headline numbers might be getting counterbalanced by some positive underlying factors.

How Do Unusual Items Influence Profit?

For anyone who wants to understand Shanghai Fosun Pharmaceutical (Group)'s profit beyond the statutory numbers, it's important to note that during the last twelve months statutory profit was reduced by CN¥1.1b due to unusual items. It's never great to see unusual items costing the company profits, but on the upside, things might improve sooner rather than later. We looked at thousands of listed companies and found that unusual items are very often one-off in nature. And that's hardly a surprise given these line items are considered unusual. In the twelve months to September 2024, Shanghai Fosun Pharmaceutical (Group) had a big unusual items expense. All else being equal, this would likely have the effect of making the statutory profit look worse than its underlying earnings power.

That might leave you wondering what analysts are forecasting in terms of future profitability. Luckily, you can click here to see an interactive graph depicting future profitability, based on their estimates.

Our Take On Shanghai Fosun Pharmaceutical (Group)'s Profit Performance

As we mentioned previously, the Shanghai Fosun Pharmaceutical (Group)'s profit was hampered by unusual items in the last year. Because of this, we think Shanghai Fosun Pharmaceutical (Group)'s underlying earnings potential is as good as, or possibly even better, than the statutory profit makes it seem! On the other hand, its EPS actually shrunk in the last twelve months. At the end of the day, it's essential to consider more than just the factors above, if you want to understand the company properly. If you want to do dive deeper into Shanghai Fosun Pharmaceutical (Group), you'd also look into what risks it is currently facing. While conducting our analysis, we found that Shanghai Fosun Pharmaceutical (Group) has 3 warning signs and it would be unwise to ignore these.

This note has only looked at a single factor that sheds light on the nature of Shanghai Fosun Pharmaceutical (Group)'s profit. But there are plenty of other ways to inform your opinion of a company. For example, many people consider a high return on equity as an indication of favorable business economics, while others like to 'follow the money' and search out stocks that insiders are buying. So you may wish to see this free collection of companies boasting high return on equity, or this list of stocks with high insider ownership.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.